Tronox Holdings Shares Plunge After Q2 Miss-March 2024-www.financetom.com

Tronox Holdings Shares Plunge After Q2 Miss

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Tronox Holdings Shares Plunge After Q2 Miss

Aug 2, 2024 10:55 AM

01:36 PM EDT, 08/02/2024 (MT Newswires) -- Tronox Holdings ( TROX ) shares were down nearly 14% in recent trading on Friday, a day after the company's Q2 results missed analysts' expectations.

The company reported Q2 adjusted earnings late Thursday of $0.07 per diluted share, down from $0.16 a year earlier. Analysts polled by Capital IQ expected $0.19.

Revenue for the quarter ended June 30 was $820 million, up from $794 million a year earlier. Analysts surveyed by Capital IQ expected $848.4 million.

Price: 13.48, Change: -2.16, Percent Change: -13.81

Previous page： Rupert Resources Edging Up As Closes $51.75 Million in Bought-Deal Equity Financing Next page： Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Rupert Resources Edging Up As Closes $51.75 Million in Bought-Deal Equity Financing

Mar 27, 2025

10:25 AM EDT, 03/27/2025 (MT Newswires) -- Rupert Resources ( RUPRF ) on Thursday closed its previously announced $51.75 million bought-deal public offering, which included the exercise in full of the underwriters' over-allotment option. The company said it plans to close its non-brokered private placement, previously announced on March 18, of up to 7.25 million common shares at the offering...

Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne

Mar 27, 2025

Dermata Therapeutics ( DRMA ), Inc. stock is trading higher on Thursday. The company, which focuses on skin diseases and aesthetic applications, released topline results from its first pivotal STAR-1 Phase 3 trial of Xyngari. The novel, once-weekly, topical product candidate for moderate-to-severe acne also appeared to be safe and well-tolerated by patients. Trial participants reported minimal treatment-related adverse events and...

Kyndryl Shares Drop After Short-Seller Gotham City Research Alleges Accounting Manipulation

Mar 27, 2025

10:23 AM EDT, 03/27/2025 (MT Newswires) -- Kyndryl ( KD ) shares declined about 11% in recent Thursday trading after short-seller Gotham City Research alleged that the company manipulates adjusted earnings before interest, taxes, depreciation and amortization and adjusted free cash flow. Gotham City claimed the manipulation aims to make it appear that the company generates profits and cash flow....

Ryanair CEO says Boeing offers backup if MAX 10 not approved soon

Mar 27, 2025

BRUSSELS (Reuters) - The head of European budget giant Ryanair praised relations with Boeing ( BA ) under its new leadership and said the planemaker had agreed to supply alternative jets in time for summer 2027 if it fails to certify its new 737 MAX 10 this year. I think we'll get our first 15 MAX 10s in 2027 but...